AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity
复制标题
DOI：
10.1038/sj.leu.2403814
复制
发表时间：
2005-08-01
期刊：
影响因子：
11.4
通讯作者：
Zimmermann, M
中科院分区：
文献类型：
--
作者：
Creutzig, U;Reinhardt, D;Zimmermann, M
尽管唐氏综合征(DS)的急性髓系白血病(AML)儿童的预后有所改善，但与治疗相关的毒性仍然是一个问题。我们比较了来自AML-BFM 98研究的67名DS患者和来自先前研究AML-BFM 93的51名DS患者，以及两项研究的非DS组。与非DS患者相比，DS患者接受了减少的蒽环类药物剂量的治疗，不使用大剂量阿糖胞苷/米托蒽醌，也不使用头颅照射。AML-DS患者年龄中位数为1.8岁，102/118(86%)表现为典型的急性巨核细胞白血病。在第93项研究中，7名DS患者没有接受AML特异性化疗，治疗修改更为常见。研究98的患者的3年存活率为91+/-4%，研究93的患者为70+/-7%(P=0.001)。0-年龄组之间的结果没有差异。
Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patients of the previous study AML-BFM 93, and the non-DS groups of both studies. Compared to non-DS patients, DS patients were treated with reduced anthracycline doses, without high-dose cytarabine/mitoxantrone and without cranial irradiation. AML-DS patients were in median 1.8 years old, and 102/118 (86%) showed the typical morphology of acute megakaryoblastic leukaemia. In study 93, seven DS patients did not receive AML-specific chemotherapy, and treatment modifications were more common. Results improved significantly for patients treated in study 98 with a 3-year survival of 91 +/- 4 vs 70 +/- 7% in study 93 (P=0.001). There were no differences in outcome concerning the age groups 0-